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Abstract
Background: Urethral stricture is a common cause of difficulty passing urine in men with prevalence of 0.5 %;
about 62,000 men in the UK. The stricture is usually sited in the bulbar part of the urethra causing symptoms such
as reduced urine flow. Initial treatment is typically by endoscopic urethrotomy but recurrence occurs in about 60 %
of men within 2 years. The best treatment for men with recurrent bulbar stricture is uncertain. Repeat endoscopic
urethrotomy opens the narrowing but it usually scars up again within 2 years requiring repeated procedures. The
alternative of open urethroplasty involves surgically reconstructing the urethra, which may need an oral mucosal
graft. It is a specialist procedure with a longer recovery period but may give lower risk of recurrence. In the absence
of firm evidence as to which is best, individual men have to trade off the invasiveness and possible benefit of each
option. Their preference will be influenced by individual social circumstances, availability of local expertise and
clinician guidance. The open urethroplasty versus endoscopic urethrotomy (OPEN) trial aims to better guide the
choice of treatment for men with recurrent urethral strictures by comparing benefit over 2 years in terms of
symptom control and need for further treatment.
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Methods/Design: OPEN is a pragmatic, UK multicentre, randomised trial. Men with recurrent bulbar urethral
strictures (at least one previous treatment) will be randomised to undergo endoscopic urethrotomy or open
urethroplasty. Participants will be followed for 24 months after randomisation, measuring symptoms, flow rate, the
need for re-intervention, health-related quality of life, and costs. The primary clinical outcome is the difference in
symptom control over 24 months measured by the area under the curve (AUC) of a validated score. The trial has
been powered at 90 % with a type I error rate of 5 % to detect a 0.1 difference in AUC measured on a 0–1 scale.
The analysis will be based on all participants as randomised (intention-to-treat). The primary economic outcome is
the incremental cost per quality-adjusted life year. A qualitative study will assess willingness to be randomised and
hence ability to recruit to the trial.
Discussion: The OPEN Trial seeks to clarify relative benefit of the current options for surgical treatment of recurrent
bulbar urethral stricture which differ in their invasiveness and resources required. Our feasibility study identified that
participation would be limited by patient preference and differing recruitment styles of general and specialist
urologists. We formulated and implemented effective strategies to address these issues in particular by inviting
participation as close as possible to diagnosis. In addition re-calculation of sample size as recruitment progressed
allowed more efficient design given the limited target population and funding constraints. Recruitment is now to
target.
Trial registration: ISRCTN98009168 Date of registration: 29 November 2012.
Keywords: Bulbar urethra, Urethral stricture, Randomised trial urethroplasty, Endoscopic urethrotomy,
Cost-effectiveness analysis
Background
Men suffer urethral stricture because of scar formation
in the urethral mucosa, which narrows the lumen. It is
the commonest cause of difficulty in passing urine among
younger and middle-aged men. The prevalence is approxi-
mately 200 per 100,000 men in their 20s rising to 900 per
100,000 men in their 70s, affecting about 62,000 men
in the United Kingdom (UK) [1]. In the National Health
Service (NHS) in England, urethral stricture in men re-
sults in 17,000 hospital admissions, 16,000 bed-days and
12,000 operations each year with an estimated cost of over
£10 million [2]. Men seek help for urethral stricture
because of progressive problems passing urine includ-
ing reduced urine flow. The site and length of a stricture is
characterised by endoscopic inspection and urethrographic
imaging, and the degree of restriction to urine flow mea-
sured by maximum flow rate (Qmax). The stricture is typic-
ally between one and five centimetres long and most (70 %)
are located in the section of urethra that runs between the
legs in the perineum (bulbar urethra). Symptomatic men
with a bulbar stricture need surgical treatment to widen the
narrowed section. The general standard approach in the
UK for newly diagnosed strictures is endoscopic urethrot-
omy where a rigid endoscope with a steel blade attached to
the end is passed into the urethra and the diseased segment
is widened by incising it longitudinally through to healthy
tissue. Cure rates for this first urethrotomy (defined as no
recurrence within 2 years) are between 40 and 70 % [3].
The target population for this clinical trial is the 30–
60 % of men with a bulbar urethral stricture who suffer
recurrence after initial surgical treatment, since the best
way to treat the recurrent stricture is uncertain. Repeat
urethrotomy and open reconstructive urethroplasty are
both reasonable options and the choice between the two
is the focus of this study. Registry data suggests repeat
urethrotomy is most often performed. It is minimally
invasive, does not require specialist surgical expertise,
and has a short period of catheterisation and recovery
[2]. However, the rate of recurrence following the second
(first repeat) urethrotomy is reported to range from 50
to 100 % (median 80 %) at 2 years [3]. Subsequent recur-
rences can lead to a chronic stricture state requiring
repeated urethrotomies, on average every 2 years during
a man’s lifetime [4]. Each urethrotomy carries a risk of
adverse effects including protracted bleeding (6 %) and
urinary tract infection (UTI; 10 %), potentially leading to
loss of quality of life, unplanned hospital admissions
and additional costs [5]. The alternative to endoscopic
urethrotomy is reconstructive open urethroplasty. The
urethra is approached through a skin incision in the
perineum behind the scrotum. The narrowed segment
is then identified and reconstructed typically using a patch
of graft material to rebuild the diseased area and perman-
ently widen the lumen [6]. The main perceived advantage
of open urethroplasty is a potentially higher rate of long-
term cure. A median success rate of 90 % freedom from
stricture recurrence at 2 years has been reported in two
systematic reviews of case series [6, 7] and is consistent
between the UK and the United States (US) [8, 9]. Wound
infection (5 %) and post-micturition dribble (10 %) are the
Stephenson et al. Trials  (2015) 16:600 Page 2 of 12
most frequently occurring adverse effects together with
pain at the graft donor site in the mouth [6, 10]. Registry
data suggests that endoscopic urethrotomy remains the
most frequently used treatment for men with recurrent
urethral strictures. Annual hospital episode statistics from
NHS England show that 818 urethroplasties of all types
were carried out in 2013–2014 compared with 9,663
endoscopic urethrotomies/urethral dilations [2]. In the
US, clinician surveys indicate that about 70 % of urologists
would advise patients to proceed to repeat urethrotomy
on initial stricture recurrence rather than consider ure-
throplasty [11]. Similarly, men undergoing urethroplasty
in the UK have had a median of four previous urethro-
tomies [12]. In the UK and the US expert opinion has
highlighted the perceived underutilisation of urethroplasty
surgery [13]. The evidence base needed to decide whether
urethroplasty is better than endoscopic urethrotomy for
men with recurrent bulbar stricture is limited by lack of
head-to-head comparison of the procedures in randomised
controlled trials (RCTs) as documented by a Cochrane
review [14].
At present, individual men have to make a trade-off be-
tween the invasiveness and presumed effectiveness of each
operation. The OPEN trial seeks to answer the following
question: in men with recurrent bulbar urethral stricture,
does open urethroplasty result in better symptom control
over 2 years than endoscopic urethrotomy and is its use
cost-effective from the perspective of the UK NHS?
The null hypothesis is that the clinical effectiveness and
cost-effectiveness of open urethroplasty is not different to
endoscopic urethrotomy. The aim of this superiority de-
sign randomised trial is to have adequate power to assess
whether open urethroplasty provides better quality of life
at an affordable cost compared with the standard proced-
ure of endoscopic urethrotomy.
Methods/Design
This is a 50-centre, pragmatic patient-randomised two-
arm superiority trial comparing, in parallel groups, open
urethroplasty (experimental) against endoscopic urethrot-
omy (standard) for men with recurrent bulbar urethral
stricture. The trial is set in a range of specialist and gen-
eral UK NHS urology units. Patients and surgeons cannot
be blinded to the allocated procedure. Central trial staff
managing and preparing trial data for analysis will be
blinded to allocated group.
Inclusion and exclusion criteria
Patient eligibility criteria are as follows:
Inclusion criteria
* Adult males aged 16 years or greater.
* Stricture located predominantly in the bulbar
urethra.
* Undergone at least one previous intervention
(endoscopic urethrotomy, urethral dilatation,
urethroplasty) for bulbar urethral stricture.
* Clinician and patient agreement that intervention is
required.
* Suitable for general or regional anaesthesia of up to
3 hours’ duration.
* Willingness to have up to a 2-week period of
catheterisation.
* Provide written informed consent for participation in
the study prior to any study-specific procedures.
Exclusion criteria
* Perineal sepsis and/or fistula.
* Not suitable for up to a 3-hour period of anaesthesia,
or inability to adhere to the trial protocol due to
co-morbidity.
* Inability to provide informed consent to
randomisation.
* Previous participation in this study.
Trial interventions
Two surgical interventions will be investigated:
1. Urethrotomy (standard)
The standard intervention of endoscopic
urethrotomy typically takes 45 minutes under
general anaesthesia, with prophylactic antibiotic
cover. With the patient’s legs partially elevated in
supporting stirrups, the endoscope is passed along
the lubricated penile urethra to locate the distal end
of the stricture. A fine-calibre wire guide is then
passed through the stricture to the bladder. Using
this guide, the stricture is progressively divided lon-
gitudinally using the mounted scalpel in the dorsal
‘12 o’clock’ orientation until the proximal
end of the stricture is reached. For short flimsy stric-
tures, dilatation with the instrument may suffice
without making a cut. The instrument is withdrawn
and a 16 French calibre silicon catheter inserted
through the urethra to the bladder and left on free
drainage [15]. The patient recovers on the ward and
is discharged according to local practice (NHS me-
dian stay is 1 day) usually with the catheter still in
place. He returns to hospital after an interval or re-
mains as an inpatient according to local practice
(typically 2–3 days) for catheter removal and voiding
check and then is followed up by outpatient review
and urinary flow rate at 3, 12 and 24 months. Ac-
cording to the clinician’s policy at individual recruit-
ing sites, and patient choice, participants may
continue a programme of intermittent self-dilation
(ISD) using a plastic catheter following urethrotomy.
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2. Urethroplasty (experimental)
Open urethroplasty involves the reconstruction of
the urethra through an appropriately sited
longitudinal skin incision made in the perineum
beneath the scrotum between the legs. It requires
pre-operative X-ray urethrography. The surgery
takes 2–3 hours under general anaesthesia with the
patient’s legs partially elevated in supports and
prophylactic antibiotic given. The bulbar urethra is
located through the skin incision and mobilised. The
strictured segment is incised longitudinally with the
cut extending into visibly healthy urethra proximally
and distally. For the majority of cases where the
stricture is relatively long and dense, a graft of oral
mucosa is inserted to widen the strictured area of
urethra (patch urethroplasty) [16]. The graft (typic-
ally 5 cm by 2 cm) is harvested according to a stand-
ard technique from the inner cheek with the donor
site left open to heal spontaneously or closed with
sutures according to surgeon practice [17].
The graft is prepared, positioned appropriately, su-
tured to the cut urethral edges, and stabilised
on the deeper tissues within the perineal wound.
This incorporates the graft mucosal surface into the
lumen of the urethra. For short supple strictures,
simple excision of the scarred area and re-joining
of the cut ends may be performed without a graft
(anastomotic urethroplasty) [18]. A 16 French
calibre silicon catheter is then passed to the bladder
and left in situ on free drainage. The patient re-
covers on the ward before discharge home (NHS
median stay is 2 days). The patient returns after an
interval according to local practice (typically 2–3
weeks) for an X-ray urethrogram to check leak-free
healing, and catheter removal. Follow-up comprises
outpatient review and urinary flow rate at 3, 12
and 24 months. Some surgeons prefer a further ure-
throgram or endoscopic examination to be per-
formed at about 12 months to ensure that no
recurrence has occurred.
Surgeons performing the procedures will be UK
consultant, accredited urologists or senior urology
trainees under consultant supervision. Endoscopic
urethrotomy is a procedure that all operating
urologists have competency for and will take place
at the hospital site where the participant was
randomised. Open urethroplasty is a specialised
procedure carried out for trial participants by
urologists recognised as being urethral surgeons
by their employing NHS organisation. The surgery
will be carried out at regional referral centres
(which are all registered sites for the OPEN trial)
to which participants will be referred using
established routine NHS pathways for undertaking
this surgery.
Identification and screening of participants
Participants will be identified by NHS clinical staff (prin-
cipally consultant and trainee urologists) at participating
centres. They will either be referrals from primary care
or men already under review in urology clinics. The clin-
ician will outline the OPEN trial and ask the patient if
they are willing to discuss participation. If they want to
know more, they will be referred to the local research
team for eligibility assessment on the same day or at a
mutually convenient time within 2 weeks.
A member of the local research team will complete a trial
screening form using information from the prospective par-
ticipant and from the clinical record to document fulfil-
ment of the entry criteria. If the patient is eligible and in
provisional agreement to participate, a local research team
member will meet with the patient either immediately in
the clinic or within 4 weeks at a mutually convenient time
and place to discuss the trial further. This initial meeting
can take place by telephone.
Recruitment procedures
Eligible participants who express interest in participating
in the OPEN trial will have the study explained to them
by local research staff and will be given a patient informa-
tion pack to read. They will be informed that the local
research team will contact them using their preferred
means of contact within 7 days to find out whether or not
they would like to take part, or alternatively to provide
further information. If they agree to take part, they will be
invited to meet with local research staff to give written
consent to be randomised between open urethroplasty
and endoscopic urethrotomy. The timing of randomisa-
tion will be according to patient and clinician wishes and
local arrangements in terms of waiting times and operat-
ing theatre list planning. These factors will be balanced as
far as possible to ensure that surgery takes place as soon
after randomisation as is acceptable to participants and
the treating NHS organisation. The trial will use existing
routine local arrangements concerning pre-assessment,
admission, consent for surgery, conduct of surgery and
after care. We will also ask men to take part in a qualita-
tive sub-study using semi-structured audio-recorded inter-
views. This will be first to assess the effect of treatment
preferences on recruitment during the initial phase of the
study and second to perform a time trade-off (TTO)
experiment during the main trial phase.
A screening log will be kept by local research staff to
document details of subjects invited to participate in the
study. Non-identifying patient details to allow assessment
Stephenson et al. Trials  (2015) 16:600 Page 4 of 12
of selection bias such as age, number and type of previous
procedures, recruitment site and length of stricture will be
uploaded to a secure study website for analysis. For sub-
jects who decline participation, this will document reasons
for non-participation.
Consent procedures
Informed consent for randomisation will be undertaken
by appropriate staff at the trial sites as detailed in the
site delegation log. This will include medical staff and
research nurses involved in the study who will give time
for participants to ask any questions they may have
following review of the trial information pack. Following
receipt of information about the study, participants will
be given at least 48 hours and up to as much time as
they need to decide whether or not they would like to
participate. Those wishing to take part will provide
written informed consent by signing and dating the
study consent form, which will be witnessed and dated
by a member of the research team with documented,
delegated responsibility to do so. Written informed
consent will always be obtained prior to randomisation
and with additional clinical consent prior to study-
specific interventions. The participant will specifically
consent to their general practitioner (GP) being in-
formed of their participation in the study. The right
to refuse to participate without giving reasons will be
respected.
Randomisation process
Eligible and consenting participants will be randomised
to one of the two intervention groups using the 24-hour
telephone Interactive Voice Response randomisation ap-
plication or via the web-based application, both hosted by
the Centre for Healthcare Randomised Trials (CHaRT) at
The University of Aberdeen, UK. The randomisation algo-
rithm will use recruitment site and time since last proced-
ure (<12 months or ≥12 months) as minimisation factors
to allocate treatment to intervention and standard groups
in a 1:1 ratio. A random element (20 %) will be incorpo-
rated into the randomisation algorithm, so that one in
five allocations will be randomly switched. The Principal
Investigator (PI) at site, or individual with delegated au-
thority, will access the telephone or web-based system
when an eligible participant has consented to participate
in the study. Patient screening identification, initials,
recruiting site and time since last intervention (stratifying
variables) will be entered into the voice-activated or web-
based system, which will return the allocation status.
Participants will be informed of their allocated treatment
group following randomisation and arrangements will be
made to carry out the procedure according to the stand-
ard process of care at the recruiting site.
Subject change of status (including withdrawal of
consent)
Patients will remain on the study unless they prospect-
ively withdraw consent for any further involvement in
the study or in the unlikely event that the PI, Chief
Investigator (CI) or trial office feel it is no longer appro-
priate for the patient to continue. Participants cannot
retrospectively withdraw consent, and any data collected
up to the point of withdrawal of consent can be used in
the analysis. If a participant wishes to change their status
in respect of full participation in the trial we will ask to
continue collecting outcome data both by posting them
symptom and quality of life questionnaires for the primary
outcome, and from their clinical records. We will, within
the consent and ethics framework, seek to complete trial
follow-up documentation as fully as possible in line with
our pre-stated intention-to-treat primary analysis. Should
a patient decide to completely withdraw from the study,
all efforts will be made to report the reason for withdrawal
as informatively as possible.
Trial procedures
Participants will complete patient-reported outcome meas-
ure (PROM) questionnaires at baseline and throughout
their trial participation. The questionnaire consists of a
six-item urinary symptom score, pictorial urine flow ques-
tion, single-item condition-specific quality of life questions
and the EuroQoL five-dimension questionnaire (EQ-5D).
The baseline and pre-intervention PROMs will be com-
pleted in hospital. A PROM will also be provided to the
participants at discharge from the hospital to complete
1 week after catheter removal. Further questionnaires will
be mailed to participants at 3, 6, 9, and 12 months post
intervention, at 18 and 24 months post randomisation,
and at the end of the study (December 2017). The timing
of follow-up points initially from intervention, and then
later in the observation period from randomisation,
ensures that participants complete an adequate number of
questionnaires whilst allowing for the time between ran-
domisation and undergoing the intervention. Participant
costs questionnaires (PCQs) will be posted to patients
at 6, and 12 months post intervention, and at 18 and
24 months post randomisation. Up to two reminders
may be sent where participants fail to return the ques-
tionnaires. In addition, participants will be reviewed in
clinic at 3 months post intervention and at 24 months
post randomisation for adverse event review and a flow
rate measurement. A further adverse event review will also
take place at 12 months post intervention, either in clinic
or during a telephone review. Case report forms (CRFs)
for each visit will be completed by the research team. If a
participant has a re-intervention whilst in the 24-month
post randomisation follow-up period this data will be
collected on an additional CRF, and patients will be asked
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to complete both a pre-intervention and 1-week post
catheter removal PROM.
Study objectives
Primary objectives are:
* To determine the relative impact on trajectory of
symptom control as measured by the International
Consultation on Incontinence Modular
Questionnaire Male Short Form (ICIQ-Male SF)
voiding symptom questionnaire over 24 months
after randomisation.
* To determine the incremental cost per quality-
adjusted life year (QALY) at 24 months after
randomisation.
Secondary objectives are:
Clinical:
* To determine the relative change in urinary flow rate
at 24 months.
* To determine the relative rate of recurrence and need
for re-intervention up to 24 months.
* To establish the safety profile of each procedure.
* To determine the relative impact of symptom control
and quality of life over the total study duration
(summarised as median time since intervention).
* To determine the relative rate of need for
re-intervention over the total study duration
(summarised as median time since intervention).
Economic:
* To estimate the incremental cost per QALY modelled
over 10 years.
Primary effectiveness outcome measure
Difference in trajectory of symptom control measured by
area under the curve (AUC) of the ICIQ-Male SF symp-
tom score [19] completed by participants during routine
clinic visits or by postal or online questionnaires at base-
line, immediately prior to surgery, 1 week after catheter
removal, at 3, 6, 9, 12 months after intervention, and at 18
and 24 months after randomisation, and additionally prior
and subsequent to any surgical re-intervention. The ICIQ-
Male SF modular questionnaire has been validated in this
patient group [20]. The trial duration allows for follow-up
of all men at 24 months after randomisation. We will also
collect longer-term follow-up data for those men who
undergo their allocated intervention earlier during the
recruitment window by completion of additional outcome
questionnaires at 24 months post surgery and at the end
of the study (December 2017).
Secondary effectiveness outcome measures
1. Difference in condition-specific quality-of-life (QoL)
trajectory measured by the AUC for the single item
ICIQ-Male SF QoL score recorded by participant
questionnaire completed during clinical visits or by
post or online at baseline, immediately prior to sur-
gery, 1 week after catheter removal, at 3, 6, 9,
12 months after intervention, and at 18 and
24 months after randomisation, and additionally
prior and subsequent to any surgical re-intervention.
2. Difference in global sexual functioning trajectory
measured by the AUC for the single-item Inter-
national Index of Erectile Function (IIEF)
male sexual QoL score recorded by participant ques-
tionnaire completed during clinical visits or by post
or online at baseline, immediately prior to surgery,
1 week after catheter removal, at 3, 6, 9, and
12 months after surgery, and at 18 and 24 months
after randomisation and prior and subsequent to any
surgical re-intervention.
3. Difference in generic QoL trajectory measured by
the AUC for the EQ-5D five-level version (5 L) ver-
sion total score based upon responses to
five-dimension items and using UK population valu-
ations (0 death to 1 full health) and visual analogue
scale score (0 worse possible health state
to 100 best possible health state). The EQ-5D will
be included in participant questionnaires adminis-
tered during routine clinical visit or by postal or
web-based participant questionnaire at baseline, im-
mediately prior to surgery, 1 week after catheter re-
moval, at 3, 6, 9 and 12 months after intervention,
18 and 24 months after randomisation, and prior
and subsequent to any surgical
re-intervention.
4. Difference in rate of improvement of urinary
flow rate measured as part of routine care at
baseline, 3 and 24 months with an increase in
Qmax ≥10 ml/s from baseline taken to signify a
successful outcome [21].
5. Difference in rate of recurrence and need for further
intervention recorded from the clinical record for
those returning to the care of their original specialist
with recurrent stricture, by patient questionnaire
for participants seeking care elsewhere, and checked
by the local trial research staff at 24 months after
randomisation. Questionnaires regarding further
intervention will be sent to participants at
24 months after their initial surgery (if this falls
before the end of the study) and also at the end
of the study (December 2017). For participants in
whom the clinical record documents stricture
recurrence but no further intervention has occurred,
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the relevant clinical information will be sent in
anonymised form as a case vignette to an expert
panel of five urology clinicians independent of the
trial to determine whether or not there is a majority
opinion that clinical recurrence of the stricture has
been confirmed.
Primary cost-effectiveness outcome measure
The primary cost-effectiveness outcome is cost-utility
measured as incremental cost per QALY at 24 months.
Utility measured by QALYs will be obtained from EQ-5D
5 L administered at the time intervals described above.
Total QALY gain for each group will be calculated by the
AUC method. QALYs from short-term impacts immedi-
ately following interventions will be estimated from a
sub-study using the TTO technique administered in a
structured interview. This will provide a more accur-
ate estimate of QALYs than that based solely on the
administration of the EQ-5D over the follow-up period.
Associated costs will be those resources required to de-
liver trial interventions, and costs incurred during follow-
up for condition-related primary and secondary care use.
Intervention-related costs will be based on participant-
level data (e.g. operating time, grade of surgeon and proto-
col deviations), other related hospitalisations and second-
ary interventions provided in hospital, outpatient visits
(number and speciality) obtained from clinical records
and the CRF. Unit costs for intervention-related resource
use will be calculated according to NHS reference cost
schedules [22] or based on study-specific estimates from
participating centres. Costs incurred during follow-up will
be estimated based on information collected in the PCQ.
Use of primary care service (number and type of GP
visits), secondary care service (hospital outpatient visits
and inpatient stay following surgery) and other healthcare
service (e.g. patients’ out-of-pocket health expenses, use of
private healthcare) will be collected from part A of the
PCQ completed at 6 and 12 months after initial surgery,
and at 18 and 24 months after randomisation. Patient time
and travel costs and other related societal costs (e.g. time
off work) will be obtained from part B of the PCQ com-
pleted at 6 months after initial surgery. Unit costs of health-
care services and medications will be based on published
sources, such as the NHS reference Healthcare Resource
Group (HRG) tariffs, the British National Formulary [23]
and Personal Social Services Research Unit [24].
Secondary cost-effectiveness outcome measures
1. Difference in mean costs calculated from the NHS
perspective and from the societal perspective [both
NHS and individual patients)].
2. Longer-term cost-utility reported as incremental
cost per QALY at 10 years. Costs and QALY up to
24 months will be based on trial data and those be-
yond 24 months will be modelled from the literature
for each trial intervention
Safety
For purposes of this protocol:
* All adverse events will be recorded as they occur at
and around the time of primary or re-intervention
surgery, and by recall at 3 months, 12 months post
surgery and 24 months post randomisation.
* Any serious adverse events will be recorded
throughout the duration of the trial.
* Serious adverse events exclude any pre-planned hos-
pitalisations (e.g. elective surgery) not associated with
clinical deterioration.
* Serious adverse events exclude routine treatment or
monitoring of the studied indication, not associated
with any deterioration in condition.
* Serious adverse events exclude elective or scheduled
treatment for pre-existing conditions that did not
worsen during the study.
* Serious adverse events exclude stricture (symptom or
urine flow) recurrence which is already documented
and monitored within study.
Recording and reporting serious adverse events or
reactions
Summary
Research team staff at individual sites will complete the
adverse events (AE) section of the relevant CRFs and
input the details of the AEs into the database hosted by
the Centre for Healthcare and Randomised Trials (CHaRT)
in Aberdeen, UK via the secure study website. The CHaRT
web-based system will automatically alert the Trial Man-
ager based in the Clinical Trials Unit, Newcastle Univer-
sity, Newcastle upon Tyne, UK if any new AEs are added
or any amendments are made to the data in existing ones.
The trial management office in Newcastle in conjunc-
tion with the Chief Investigator (CI) will have the
responsibility for any decision making and forward
reporting of AEs. All AEs should be recorded in the
CRF. Suspected unexpected serious adverse events
(SUSARs) that are considered to be causally related
will be separately reported on the specific form.
Adverse events that are serious but expected will not
be reported on the SUSAR form.
Adverse events (AEs) All AEs during study participation
will be reported on the study CRF and entered by local
investigators into the trial web management system. The
individual investigator at each site will be responsible for
managing all AEs according to local arrangements.
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Serious adverse events (SAEs) All unexpected SAEs
that are related or of uncertain causality during study
participation shall be reported to the CI through the
study website within 24 hours of the site learning of
its occurrence. The initial report will be made by com-
pleting the electronic SUSAR form which will automatic-
ally send e-mail notification to the Trial Manager and CI
in Newcastle. In the case of incomplete information
at the time of initial reporting, all appropriate infor-
mation should be provided as follow-up as soon as
this becomes available. Relationship of the SAE to trial
participation should be assessed by the investigator at site,
as should the expected or unexpected nature of the AE.
The Research Ethics Committee (REC) will be notified by
the CI (on behalf of the Sponsor; The Newcastle upon
Tyne Hospitals NHS Foundation Trust) of all SUSARs
within 15 days of the CI becoming aware of the SUSAR
(unless urgent safety measures are required, in which case
initial notification by telephone will be made immediately
the CI becomes aware of the AE, with notice in writing
following within 3 days). SUSARs will be reported using
the National Research Ethics Committee (NRES) Report
of Serious Events Form, version 3, April 2007 [25]. The CI
will ensure that the Sponsor is notified of any SUSARs in
accordance with local trust policy. Local investigators
should report any SUSARs as required by their local NHS
Trust Research and Development Office.
Statistical analysis
The primary outcome, AUC for the ICIQ-Male SF symp-
tom score, will be generated for each participant using the
trapezoidal rule. Symptom score data for participants who
have missed a scheduled time point will be estimated
using a multiple imputation approach to make use of
partial outcome data [26]. Sensitivity analyses will be
conducted to assess the robustness of the treatment
effect estimate to these approaches. The primary out-
come measure will be analysed using linear regression
with adjustment for the minimisation variables [site of
recruitment and time since last procedure (<12 months or
≥12 months)]. The main statistical analyses will be based
on all participants as randomised, irrespective of subse-
quent compliance with the treatment allocation. Second-
ary outcomes will be analysed using generalised linear
models with adjustment for minimisation and baseline
variables as appropriate. All estimates will be presented
with 95 % confidence intervals. Subgroup analyses will
explore the possible modification of treatment effect by
clinically important factors; time since last procedure
(<12 months or ≥12 months) as a global measure of
stricture severity, age, stricture location, and length. This
will be done by including treatment-by-factor interactions
in the model. All analyses will initially be performed on an
intention-to-treat basis. We will consider additional ana-
lyses such as per-protocol depending on the levels of
compliance with allocated treatment. Further analysis will
explore the impact of variations in treatment delivered;
such as use of anastomotic urethroplasty, use of intermit-
tent self-dilatation after urethrotomy, and delay between
decision to treat and undergoing the intervention. From
the initial phase of recruitment we will report estimates of
recruitment rates and potential participant availability,
together with appropriate confidence intervals. There are
no planned interim outcome analyses; all analyses will
occur following completion of trial follow-up. Interim
analyses will be performed if requested by the Data Moni-
toring and Ethics Committee (DMC). All analyses will
be outlined in detail in a pre-specified statistical ana-
lysis plan.
Sample size calculation
We initially planned to recruit 500 participants to the
study. This used the assumption that the standard devi-
ation (SD) of the primary outcome measure (ICIQ-Male
SF questionnaire score 0–24) would be 0.3. Using this
figure with 90 % power (two-sided 5 % significance
level), 235 participants per group (470 in total) would
have been required. This would equate to being able to
detect at least a 0.1 difference in the AUC on the
standardized 0–1 utility scale, assuming a SD of 0.33 or
less. The SD of the ICIQ-Male SF symptom AUC in a
previous study was 0.15 [20]. Given our lack of more
precise information, we initially conservatively allowed
for a larger SD in recognition of the less selected, more
pragmatic (i.e. more representative) population to be
recruited to this trial and the shorter follow-up period in
the previous study. Such a difference in symptom bur-
den and associated QoL has been observed in different
clinical areas for health-related quality-of-life (HRQoL)
measures [27]. In terms of treatment effect size, this is
in the small to medium range as observed in other
clinical studies [28]. To allow for the anticipated ap-
proximately 5 % of participants for whom outcome data
is completely missing, and therefore the AUC cannot be
calculated, it was initially proposed to randomise 500
participants. The slower than initially expected recruit-
ment rate has allowed us to use blinded trial outcome
data to provide a more precise estimate of the SD. We
have calculated the SD of the patient-reported symptom
score (primary outcome measure) from 69 active OPEN
participants who have submitted at least one post-
operative measure (220 measurements in total). The re-
calculation gives an SD value of 0.165, which reduces to
0.15 when adjusted for baseline score and centre, con-
siderably smaller than the assumed value of 0.33, which
was used in our initial calculations. Using this SD in our
sample size calculation would indicate a target
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population of 96 participants. However, no 18 or
24 month data are currently available and variability
would be expected to increase over time. Allowing for
this and other factors increasing variability we have as-
sumed a SD of 0.21 or less. This would require 186 ran-
domised men with complete follow-up inflated to 200 in
total to allow for loss to follow-up. Based on findings
from recruitment to the ProtecT trial, which randomises
between surgery and less invasive options for men with
localised prostate cancer, we originally conservatively es-
timated a 55 % agreement to participate rate amongst
those eligible requiring 910 men to be approached [29].
We have reassessed this in the light of slower than antic-
ipated recruitment rate from screening data from the
trial now available to us showing a 22 % agreement to
participate rate. For the qualitative interview study we
estimate, based on previous experience in such method-
ology, that up to 10 men who agree, and up to 10 men
who do not agree to be randomised and up to 12 pur-
posively sampled specialist and general urologists will be
required to achieve data saturation for thematic analysis.
The trial is also secondarily powered to determine
whether the use of urethroplasty will result in a 30 %
(from 50 % to 20 %) reduction in need for further inter-
vention at 2 years compared to urethrotomy as a second-
ary outcome. To detect this difference using the binomial
test of proportions with 90 % power at the 5 % significance
level would require 48 men to complete the study in each
arm.
Economic analysis
For the within-trial analysis the primary measure of
effectiveness will be incremental QALY gain based on
responses to the EQ-5D over a 24-month time hori-
zon. Cumulative mean costs to patients and the NHS
over the trial follow-up period for each intervention
will be estimated from patient and NHS resource use
data collected during the trial and their unit costs based
on standard sources. The difference between mean costs
between the two arms will be combined with their relative
effectiveness to produce an incremental cost per QALY
gained at 24 months. Methods such as bootstrapping will
be used to produce confidence intervals around difference
in costs and effects. The same method will be used to
produce cost-effectiveness acceptability curves. Sensitivity
analysis will be used to explore other uncertainties such as
alternative cost estimates. Open urethroplasty is expected
to be both more effective and more costly than endo-
scopic urethrotomy, and its benefits may persist beyond
24 months. Therefore, we will conduct a cost-utility ana-
lysis using a Markov model with 10-year time horizon to
compare incremental cost, incremental QALY and incre-
mental cost per QALY of the interventions. The model
structure will be based upon care pathways mapped out
by the project team and the literature. Guidelines for best
practice for modelling will be followed [30]. Trial data will
be a vital source to populate the model, and additional
data on care and events beyond 24 months will be based
on structured literature review. Specific trial data will
include effectiveness and costs of the interventions and
ongoing care for participants whose strictures recur.
Utility scores will be calculated based on responses to
the EQ-5D from participants whose strictures do not
require re-intervention, and from those having AEs.
These will be cross validated with existing values [31].
We will also conduct extensive probabilistic sensitivity
analyses by attaching appropriate distributions to the
model input parameters. The results of these analyses
will be presented as cost-effectiveness acceptability
curves. Deterministic sensitivity analyses will be used
to explore other forms of uncertainty such as varying
the model’s time horizon. As the duration of follow-up
in both the within-trial and the model-based analyses
is greater than 1 year both costs and effects will be
discounted at 3.5 % [32].
Ethics and regulatory issues
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions. Favourable
ethical opinion to carry out the research across all UK
NHS organisations was granted by the UK National
Research Ethics Committee North East - Newcastle and
North Tyneside 1 (reference 12/NE/0343). The Research
and Development (R&D) Department of The Newcastle
upon Tyne Hospitals NHS Foundation Trust is the Trial
Sponsor. Local approvals will be sought before recruit-
ment may commence at each site. The Study Coordin-
ation Centre will require a written copy of local approval
documentation before initiating each centre and accept-
ing participants into the study. Information sheets will
be provided to all eligible subjects and written informed
consent obtained prior to any study procedures.
Discussion
There is continued uncertainty amongst clinicians and
men suffering recurrent bulbar urethral stricture whether
urethroplasty or urethrotomy represent the best treatment
with no new trials identified in a recently updated
Cochrane review [14]. This in turn makes it difficult for
providers of healthcare to plan appropriate services. The
OPEN trial therefore remains necessary to provide the
required evidence of effectiveness and cost-effectiveness.
The timely recruitment of sufficient numbers of trial
participants has been the key challenge to date (June
2015) for the OPEN trial. The incidence of recurrent
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bulbar urethral stricture is relatively low, so identifying
potential participants has been difficult. Furthermore,
eligible patients have the option of either treatment in
standard care (urethrotomy or urethroplasty), and as a
result they are more inclined to follow their individually
preferred treatment pathway rather than accepting ran-
domisation. This may be exacerbated by clinicians stating
that one option is better than another. In the screening
data collected to date, 66 % of potentially eligible patients
declined entry to the trial due to having a preference for
either treatment.
Data collection through return of PROMs has remained
high throughout the trial (75–100 % return rate for differ-
ing time points). This is attributed to strategies designed to
encourage men to return their PROMs; e-mail and/or text
pre-notification of PROM delivery, mailed and telephone
reminders of overdue PROMs, and monetary ‘thank you’
gifts (£25 gift voucher after randomisation, £25 gift vou-
cher at 24 months after randomisation, and a further £25
gift voucher after completion of all follow-up data). The
lowest return rate for the PROMs was at the 1-week post
catheter removal time point (currently at 68 % return).
These were initially sent by post to the patient after their
surgery, which relied on the sites uploading the dates of
surgery and catheter removal into the e-CRF immediately.
Sites were then encouraged to give the patient these
PROMs at discharge, which has caused an improvement in
the return rates.
Waiting times for surgery vary between each partici-
pating centre, and between each arm of the trial. For this
reason, two anchor points were decided upon for follow-
up analysis; for the primary analysis anchoring follow-up
to a fixed 2-year post randomisation point will allow for
analysis of symptom control and quality of life from the
initial decision to treat, providing a pragmatic approach
to account for the difference in waiting times for each
intervention. As a secondary outcome we will additionally
analyse symptom control and quality of life over the
total study duration (summarised by median time since
intervention) giving additional information on longer
duration of follow-up for men after undergoing the stud-
ied interventions.
Strategies used to optimise identification and
randomisation of men willing to participate
High-quality randomised clinical trials remain essential
to clarify the comparative effectiveness of treatments for
conditions where differing therapeutic options are pos-
sible. However recruitment is often challenging, particu-
larly when the options being compared are both available
as is the case for the OPEN trial. As the trial has pro-
gressed we have used a number of strategies to ensure that
men eligible for inclusion and who are willing to take part
have the opportunity to participate in OPEN.
1. Inclusion and interpretation of feasibility phase:
the pre-planned feasibility phase of OPEN allowed
realistic estimate of the required duration of recruit-
ment period and the optimum number of centres re-
quired to be set up. Detailed discussion of the issues
and potential solution with the funder facilitated ne-
cessary changes to trial design allowing
continuation.
2. Completion of qualitative work to establish factors
determining willingness of patients and support of
their clinicians to consider participation: timely and
successful completion of a planned qualitative study
first established that the aims of the trial were
important to men eligible to participate given the
troublesome and chronic nature of their symptoms
and reinforced the rationale and need for the trial
[33]. As part of this work, we found that men
eligible for inclusion were most likely to be willing
to participate when their symptoms had first
recurred and this was the point at which they
expressed most uncertainty as to which option
would be best for them as individuals. Both general
and specialist clinicians were also very supportive
of the aims of the trial given the uncertainty of
guidance on best treatment, but expressed concerns
regarding delivery of balanced information to men
eligible for participation. Appropriate written
guidance and an example video were provided to
assist supported by personal contact from the trial
team.
3. Establishment of general urology centres as recruiting
sites: most men eligible for the trial present initially
to general urology units prior to potential referral to
specialist urethral surgeons. This was established as
the main focus of recruitment as the results of the
trial will in future inform decision making around
referral. We selected sites with a motivated urologist
Principal Investigator and encouraged realistic
prediction of likely number of men identified and
consenting to randomisation. Visits by the Chief
Investigator to go through local difficulties were
offered and carried out.
4. Sharing of experience: representatives from all sites
were invited to take part in regular telephone
conferences facilitated by the central trial team
and bi-monthly e-newsletters were circulated to en-
courage sharing of local difficulties and their
solutions.
Trial status
The first participant was recruited in February 2013. The
trial is currently open to recruitment in 50 UK centres.
Recruitment is scheduled to finish in December 2015 with
follow-up complete at December 2017. Up to the end of
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November 2015; 214 participants have been enrolled
against the target of 210. In line with current trial protocol
reporting recommendations we include a SPIRIT checklist
(Additional file 1) and administrative details concerning
trial conduct (Additional file 2).
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to
address in a clinical trial protocol and related documents*.
(DOC 120 kb)
Additional file 2: Administrative details. (DOCX 27 kb)
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